Scilex Holding Company (SCLX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Scilex Holding Company (SCLX) has a cash flow conversion efficiency ratio of 0.022x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-6.74 Million) by net assets ($-310.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Scilex Holding Company market capitalisation for the company's overall valuation and market capitalisation.
Scilex Holding Company - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Scilex Holding Company's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Scilex Holding Company Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scilex Holding Company ranked by their cash flow conversion efficiency. Explore Scilex Holding Company earnings quality ratio to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jaba I Inversiones Inmobiliarias Socimi SA
MC:YABA
|
0.001x |
|
TGI Infrastructures Ltd
TA:TGI
|
0.069x |
|
GigCapital7 Corp. Class A Ordinary Share
NASDAQ:GIG
|
-0.052x |
|
WIZIT Co. Ltd
KQ:036090
|
0.055x |
|
Reino Capital SA
WAR:RNC
|
0.064x |
|
MNC Vision Networks PT
JK:IPTV
|
0.015x |
|
Hankuk Steel Wire Co. Ltd
KQ:025550
|
-0.012x |
|
Comunication Weaver Co.Ltd
KQ:056360
|
-0.020x |
Annual Cash Flow Conversion Efficiency for Scilex Holding Company (2020–2025)
The table below shows the annual cash flow conversion efficiency of Scilex Holding Company from 2020 to 2025. View current stock price of Scilex Holding Company for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-211.75 Million | $3.82 Million | -0.018x | +82.06% |
| 2024-12-31 | $-192.64 Million | $19.35 Million | -0.100x | -183.88% |
| 2023-12-31 | $-172.94 Million | $-20.71 Million | 0.120x | +120.41% |
| 2022-12-31 | $36.24 Million | $-21.26 Million | -0.587x | -558.16% |
| 2021-12-31 | $-223.88 Million | $-28.66 Million | 0.128x | -42.34% |
| 2020-12-31 | $-141.68 Million | $-31.46 Million | 0.222x | -- |
About Scilex Holding Company
Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve… Read more